AbbVie opens up to bigger deals as competition heats up — report; Small radiopharmaceutical player goes public via reverse merger
AbbVie is looking to make a push this year on new drugs — and it’s ready to spend for it.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.